
Brian Lian, Viking Therapeutics CEO
Viking Therapeutics plans Ph2 trial for oral obesity drug after positive early-stage data
Viking Therapeutics touted early-stage obesity data showing its oral GLP-1/GIP dual agonist produced 5.3% weight loss and few side effects, sending the company’s stock …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.